Less Ads, More Data, More Tools Register for FREE

Pin to quick picksChemring Regulatory News (CHG)

Share Price Information for Chemring (CHG)

Share Price is delayed by 15 minutes
Get Live Data
500.00    0.60 (0.12%)
Bid:
498.00
Ask:
500.50
Spread: 2.50 (0.502%)
Market Cap: £1.35b
CHG Live PriceLast checked at - London Stock Exchange

Intraday Chemring Share Chart

Trading Update

5 Sep 2017 07:00

RNS Number : 7865P
Chemring Group PLC
05 September 2017
 

FOR IMMEDIATE RELEASE 5 SEPTEMBER 2017

 

CHEMRING GROUP PLC

TRADING UPDATE

 

Chemring Group PLC ("Chemring" or "the Group") today issues a trading update for the four month period from 1 May to 31 August 2017.

 

Current trading

Revenue in the period was £156.7 million, an increase of 13.4% compared with £138.2 million in the same period last year.

 

Trading in the period has progressed as planned and the Board's current expectations for the year ending 31 October 2017 remain unchanged. 

 

The Group's order book at 31 August 2017 was £541.8 million, 2.6% lower than the order book of £556.2 million at 30 April 2017. Recent orders received, for delivery in FY18, give us increased confidence in the Group's prospects in the near term.

 

Segmental update

The period has seen a particularly strong performance from the countermeasures segment, with orders totalling £56.6 million received, operational performance improving and the second Philadelphia plant successfully closed. The majority of these orders were from the US Government for a range of requirements.

 

In Sensors, trials of enhanced Husky Mounted Detection Systems have been successfully completed in theatre and we are currently working with the customer base to define the next phase of fleet refurbishment and upgrade and next generation development requirements.

 

Performance across the entire Energetics segment has been robust through the period. Of particular note, Chemring Ordnance has been awarded a contract for the supply of 40mm ammunition to an international customer, valued at approximately US$30.0 million. The Group is currently awaiting the receipt of the cash advance payment and associated export licences, which are expected shortly. Subject to the receipt of this documentation, deliveries are expected to be made in the final quarter. The associated revenue and profit is assumed within our FY17 outlook comment above.

 

Financial position

Net debt at 31 August 2017 was £125.8 million (30 April 2017: £111.7 million). As expected, the forecast phasing of trading in FY17 results in a weighting of operating cash generation to Q4.

 

-ENDS-

 

For further information:

Rupert Pittman Group Director of Corporate Affairs, 01794 833901

Chemring Group PLC

 

Andrew Jaques MHP Communications 0203 128 8100

James White

 

Cautionary statement

 

This announcement contains forward-looking statements that are based on current expectations or beliefs, as well as assumptions about future events. These forward-looking statements can be identified by the fact that they do not relate only to historical or current facts. Forward-looking statements often use words such as anticipate, target, expect, estimate, intend, plan, goal, believe, will, may, should, would, could, is confident, or other words of similar meaning. Undue reliance should not be placed on any such statements because they speak only as at the date of this document and, by their very nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause actual results, and Chemring's plans and objectives, to differ materially from those expressed or implied in the forward-looking statements. There are a number of factors which could cause actual results to differ materially from those expressed or implied in forward-looking statements. Among the factors that could cause actual results to differ materially from those described in the forward-looking statements are: increased competition, the loss of or damage to one or more key customer relationships, changes to customer ordering patterns, delays in obtaining customer approvals for engineering or price level changes, the failure of one or more key suppliers, the outcome of business or industry restructuring, the outcome of any litigation, changes in economic conditions, currency fluctuations, changes in interest and tax rates, changes in raw material or energy market prices, changes in laws, regulations or regulatory policies, developments in legal or public policy doctrines, technological developments, the failure to retain key management, or the key timing and success of future acquisition opportunities or major investment projects. Chemring undertakes no obligation to revise or update any forward-looking statement contained within this announcement, regardless of whether those statements are affected as a result of new information, future events or otherwise, save as required by law and regulations.

 

Notes to editors

· Chemring is a global business that specialises in the manufacture of high technology products and the provision of services to the aerospace, defence and security markets

· Employing approximately 2,500 people worldwide, and with production facilities in four countries, Chemring meets the needs of customers in more than fifty countries

· Chemring is organised under three strategic product segments: Countermeasures, Sensors & Electronics, and Energetic Systems

· Chemring has a diverse portfolio of products that deliver high reliability solutions to protect people, platforms, missions and information against constantly changing threats

· Operating in niche markets and with strong investment in research and development ("R&D"), Chemring has the agility to rapidly react to urgent customer needs

 

www.chemring.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKQDBABKDPCK
Date   Source Headline
21st Jan 20167:00 amRNS£80.8 million Rights Issue
21st Jan 20167:00 amRNSFinal Results
20th Jan 20164:01 pmRNSDirector/PDMR Shareholding
4th Jan 201610:01 amRNSTotal Voting Rights
21st Dec 201511:19 amRNSBlocklisting Update
21st Dec 201511:17 amRNSBlocklisting Interim Review
1st Dec 20159:57 amRNSTotal Voting Rights
25th Nov 20157:00 amRNSPOST-CLOSE STATEMENT
2nd Nov 201511:21 amRNSHolding(s) in Company
27th Oct 20157:00 amRNSTrading Statement
1st Oct 201511:15 amRNSTotal Voting Rights
29th Sep 20152:25 pmRNSHolding(s) in Company
14th Sep 20157:00 amRNSTrading Update
1st Sep 20159:33 amRNSTotal Voting Rights
20th Aug 20153:01 pmRNSHolding(s) in Company
7th Aug 20151:56 pmRNSHolding(s) in Company
3rd Aug 20159:28 amRNSTotal Voting Rights
1st Jul 20152:47 pmRNSTotal Voting Rights
24th Jun 20155:26 pmRNSHolding(s) in Company
23rd Jun 20157:00 amRNSHalf Yearly Report
19th Jun 20158:55 amRNSBlocklisting Update
19th Jun 20157:00 amRNSBlocklisting Interim Review
11th Jun 201510:02 amRNSAdditional Listing
2nd Jun 20157:00 amRNSTotal Voting Rights
1st May 201512:01 pmRNSTotal Voting Rights
10th Apr 201511:59 amRNSTotal Voting Rights
19th Mar 20152:21 pmRNSResult of AGM
19th Mar 20157:00 amRNSAGM Statement
2nd Mar 20151:41 pmRNSTotal Voting Rights
2nd Feb 20151:16 pmRNSTotal Voting Rights
27th Jan 20154:10 pmRNSDirector/PDMR Shareholding
27th Jan 20154:09 pmRNSDirector/PDMR Shareholding
27th Jan 20154:08 pmRNSDirector/PDMR Shareholding
27th Jan 201512:25 pmRNSDirector/PDMR Shareholding
27th Jan 201512:11 pmRNSDirector/PDMR Shareholding
27th Jan 201512:08 pmRNSDirector/PDMR Shareholding
27th Jan 201512:03 pmRNSDirector/PDMR Shareholding
23rd Jan 20154:33 pmRNSDirector Declaration
22nd Jan 20157:00 amRNSFULL YEAR RESULTS
2nd Jan 201512:59 pmRNSTotal Voting Rights
30th Dec 20147:00 amRNSDirectorate Change
19th Dec 201410:26 amRNSBlocklisting Interim Review
1st Dec 20141:26 pmRNSHolding(s) in Company
1st Dec 20141:22 pmRNSTotal Voting Rights
25th Nov 20147:00 amRNSPOST-CLOSE STATEMENT
3rd Nov 20142:36 pmRNSTotal Voting Rights
1st Oct 201410:04 amRNSTotal Voting Rights
17th Sep 20147:00 amRNSInterim Management Statement
1st Sep 20142:52 pmRNSTotal Voting Rights
8th Aug 201412:28 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.